Key Takeaways:
GE HealthCare Technologies Inc. (GEHC) saw its stock price fall 6.6% after the company’s first-quarter adjusted earnings per share for 2026 failed to meet Wall Street expectations.
The report on April 29 was highly anticipated, with analysts setting a consensus estimate of $1.07 for adjusted earnings per share on revenues of $5.05 billion, according to Zacks Investment Research. The company's failure to meet the EPS target triggered the sharp sell-off in its shares.
While the exact figures are being digested by the market, the earnings miss confirms investor fears heading into the report. Below is a summary of the consensus expectations:
The negative result puts pressure on the company, which has been navigating several headwinds. Analysts had flagged ongoing market weakness in China and the impact of tariffs as potential drags on profitability. The delayed commercial rollout of some new products was also cited as a concern.
Prior to the release, analysts expected mixed results across GE HealthCare's segments. The Pharmaceutical Diagnostics business was forecast to be a key growth driver, buoyed by strong demand for contrast media and radiopharmaceuticals.
However, the Imaging segment's margins were expected to remain under pressure from tariffs, despite stable demand in developed markets. The Patient Care Solutions division was also watched for potential year-over-year weakness due to unfavorable product mix dynamics.
The earnings miss suggests these headwinds may have had a greater impact than anticipated. The company entered the quarter with a record $21.8 billion backlog, which provides some revenue visibility, but profitability remains a key focus for investors.
The 6.6% decline brings GE Healthcare's year-to-date share price loss to nearly 20%, underperforming the S&P 500. Investors will now look to the upcoming analyst call for details on management's plan to address the earnings shortfall and for any revisions to full-year guidance.
This article is for informational purposes only and does not constitute investment advice.
